FDA Priority-Setting Includes Fewer Meetings With NDA Sponsors
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of New Drugs Director Jenkins tells DIA that agency is making “strategic decisions” about how many sponsor meetings it can schedule.